18F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients: A multicenter retrospective cohort study

Sae Jung Na, Jin Kyoung Oh, Seung Hyup Hyun, Jeong Won Lee, Il Ki Hong, Bong Il Song, Tae Sung Kim, Jae Seon Eo, Sung Won Lee, Ie Ryung Yoo, Yong An Chung, Mijin Yun

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) consists of a heterogeneous group of patients with a wide range of survival times, requiring further prognostic stratification to facilitate treatment allocation. We evaluated the prognostic value of 18F-FDG uptake on PET/CT at the time of presentation in patients with BCLC stage C HCC. Methods: A total of 291 patients with BCLC stage C HCC who underwent 18F-FDG PET/ CT between 2009 and 2010 for staging were retrospectively enrolled from 7 university hospitals. The patients were further divided into 2 groups according to the extent of disease, as intrahepatic or extrahepatic. Tumor-to-liver SUV ratio (TLR) of the primary tumor was measured on 18F-FDG PET/CT. Prognostic values of TLR and other clinical variables were analyzed to predict overall survival (OS) in univariate and multivariate analyses. Differences in the OS stratified by TLR were examined by the Kaplan-Meier method. Results: Higher TLR was associated with extrahepatic disease (P = 0.018). On multivariate analysis, Child-Pugh classification and TLR were independent prognostic factors in the intrahepatic disease group (all P < 0.05), whereas TLR was the only independent prognostic factor in the extrahepatic disease group (P < 0.05). Patients with high TLR showed a significantly worse OS than those with low TLR (P < 0.05) in both groups. Conclusion: In patients with BCLC stage C HCC, 18F-FDG uptake in the primary tumor was significantly higher in patients with extrahepatic disease than in those with intrahepatic disease. In addition, 18F-FDG uptake on pretreatment PET/CT had an incremental prognostic value for OS in both intrahepatic and extrahepatic disease groups.

Original languageEnglish
Pages (from-to)730-736
Number of pages7
JournalJournal of Nuclear Medicine
Volume58
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Keywords

  • F-FDG
  • Hepatocellular carcinoma
  • PET/CT
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '<sup>18</sup>F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients: A multicenter retrospective cohort study'. Together they form a unique fingerprint.

  • Cite this

    Na, S. J., Oh, J. K., Hyun, S. H., Lee, J. W., Hong, I. K., Song, B. I., Kim, T. S., Eo, J. S., Lee, S. W., Yoo, I. R., Chung, Y. A., & Yun, M. (2017). 18F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients: A multicenter retrospective cohort study. Journal of Nuclear Medicine, 58(5), 730-736. https://doi.org/10.2967/jnumed.116.182022